netFormulary NHS
Herefordshire & Worcestershire
Medicines and Prescribing Committee
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Alectinib (Alecensa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For untreated ALK-positive advanced non-small-cell lung cancer in line with NICE TA536. 

 
Link  Link to CDF secure application site
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
 
Avelumab (Bavencio®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating metastatic Merkel cell carcinoma, in line with NICE TA517.

 
Link  Link to CDF secure application site
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
 
Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For treating advanced renal cell carcinoma after failure of prior systemic treatment in line with NICE TA333.


Commissioned by NHSE

 
Link  NICE TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
 
Cytotoxic Drug Bendamustine
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

 

For the first-line treatment of chronic lymphocytic leukaemia in line wiith NICE TA216

 

In combination with obinutuzumab for treating follicular lymphoma after rituximab, in line with NICE TA629

 

 
Link  Link to CDF secure application site
Link  NICE TA216 Bendamustine for CLL
Link  NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
 
Brentuximab (Adcetris®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

 

For relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE TA478

 

For CD30-positive Hodgkin lymphoma in line with NICE TA524 . 

 

For CD30-positive cutaneous T-cell lymphoma in line with NICE TA577 

 

 
Link  Link to CDF secure application site
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
 
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For hormone-refractory metastatic prostate cancer previously treated with docetaxel in line with NICE TA 391

 
Link  Link to CDF secure application site
Link  NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
 
Cabozantinib (Cabometyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating Previously treated advanced renal cell carcinoma in line with NICE TA463 and untreated advanced renal cell carcinoma in line with NICE TA542.

 
Link  Link to CDF secure application site
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
 
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating medullary thyroid cancer in line with NICE TA516.

 
Link  Link to CDF secure application site
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
 
Ceritinib (Zykadia®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer in line with NICE TA395

For untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults in line with NICE TA500

 

 
Link  Link to CDF secure application site
Link  NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
 
Crizotinib (Xalkro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA406 and TA422

NICE TA406 & NICE TA422:Crizotinib is recommended, within its marketing authorisation, as an option for untreated anaplastic/previously treated lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.


 
Link  Link to CDF secure application site
Link  NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  MHRA Drug Safety Update: Crizotinib (Xalkori®▼): risk of cardiac failure
 
Dabrafenib (Tafinlar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Specialist centre prescribing only in line with NICE TA321

 
Link  Link to CDF secure application site
Link  NICE TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
 
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA423

Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when:
•it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
•the company provides eribulin with the discount agreed in the patient access scheme

 
Link  Link to CDF secure application site
Link  NICE TA423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
 
Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA429
Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:
•who have had at least 1 prior therapy or
•who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and
•only when the company provides Ibrutinib with the discount agreed in the patient access scheme

 
Link  Link to CDF secure application site
Link  NICE TA429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
 
Idelalisib (Zydelig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA359 
Recommended for untreated CLL in adults with a 17p deletion or TP53 mutation, or for previously-treated CLL when relapsed within 24 months. Idelalisib is recommended only if the company provides the drug with the discount agreed in the simple discount agreement.

 
Link  NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia
 
Ipilimumab (Yervoy® )
View adult BNF View SPC online View childrens BNF
Formulary
Red

Recommended for previously treated advanced (unresectable or metastatic) melanoma as an option for treating advanced (unresectable or metastatic) melanoma in people who have received prior therapy, only if the manufacturer provides ipilimumab with the discount scheme agreed in the patient access scheme in line with NICE TA 268.

Ipilimumab is recommended as a possible treatment for adults with advanced (unresectable or metastatic) melanoma that has not been treated before in line with NICE TA319.

 
Link  NICE TA268 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
 
Ixazomib (Ninlaro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults in line with NICE TA505.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
 
Lenvatinib (Lenvima®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating differentiated thyroid cancer after radioactive iodine as per NICE TA535 


For untreated advanced hepatocellular carcinoma as per NICE TA551 

 
Link  Link to CDF secure application site
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551:Lenvatinib for untreated advanced hepatocellular carcinoma
 
Nintedanib (Vargatef®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA347
-when given in combination with docetaxel (please see guidance for further details)
Funded by NHS England when used for Non-Small Cell Lung Cancer


Commissioned by NHSE

 
Link  NICE TA347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
 
Nivolumab (Opdivo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Nivolumab as monotherapy is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults in line with NICE TA384

Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults in line with NICE TA400

Recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults in line with NICE TA417 

 
Link  Link to CDF secure application site
Link  NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417 Nivolumab for previously treated advanced renal cell carcinoma
 
Ofatumumab (Arzerra® )
View adult BNF View SPC online View childrens BNF
Formulary
Red


Recommended in combination with chlorambucil as an option for untreated chronic lymphocytic leukaemia in line with NICE TA344.

 
Link  NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
 
Cytotoxic Drug Olaparib  (Lynparza®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
 
Link  Link to CDF secure application site
 
Osimertinib (Tagresso ®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Osimertinib is recommended as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only:
-after first-line treatment with an EGFR tyrosine kinase inhibitor and
-if the conditions in the managed access agreement for osimertinib are followed


in line with NICE TA416

 
Link  Link to CDF secure application site
Link  NICE TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
 
Cytotoxic Drug Panitumumab  (Vectibix®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA439
Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with:
-FOLFOX or
-FOLFIRI 
The drugs are recommended only when the companies provide them with the discounts agreed in their patient access schemes.

 
Link  Link to CDF secure application site
Link  NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
 
Panobinostat  (Farydak®)
View adult BNF View SPC online
Formulary
Red

In line with NICE TA380
in combination with bortezomib and dexamethasone is recommended, within its marketing authorisation, as an option for treating multiple myeloma, that is, for ’adult patients with relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent’ when the company provides panobinostat with the discount agreed in the patient access scheme.

 
Link  NICE TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments
 
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For first-line treatment of advanced renal cell carcinoma in line with NICE TA215


Commissioned by NHSE

 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
 
Pembrolizumab  (Keytruda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA357, TA366 and TA428

 


Commissioned by NHSE

 
Link  NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
 
Cytotoxic Drug Pertuzumab (Perjeta® )
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA424
Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2) positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence.
It is recommended only if the company provides pertuzumab with the discount agreed in the patient access scheme.


 
Link  Link to CDF secure application site
Link  NICE TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
 
Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red


In line with NICE TA386:


Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:
-in people with intermediate-2 or high-risk disease,
-and if the company provides ruxolitinib with the discount agreed in the patient access scheme

Commissioned by NHSE

 
Link  NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
 
Trametinib (Mekinist®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA396:
Trametinib in combination with dabrafenib is recommended as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation

 
Link  Link to CDF secure application site
Link  NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
 
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme, in line with NICE TA269.


Commissioned by NHSE

 
Link  MHRA Drug Alert (Nov 15): Vemurafenib (Zelboraf®▼): risk of potentiation of radiation toxicity
Link  NICE TA269 Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
 
Venetoclax  (Venclyxto® )
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating chronic lymphocytic leukaemia as per NICE TA487 

For previously treated chronic lymphocytic leukaemia in combination with Rituximab as per NICE TA561 

 
Link  Link to CDF secure application site
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
 
08.01.05  Expand sub section  Amsacrine
Cytotoxic Drug Amsacrine (Amsidine®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
Cytotoxic Drug Bevacizumab (Avastin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
 
Link  Link to CDF secure application site
 
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

in line with NICE TA129, TA228, TA311 and TA370.


 
Link  Link to CDF secure application site
Link  NICE TA129 Bortezomib monotherapy for relapsed multiple myeloma
Link  NICE TA228 Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Link  NICE TA311 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Link  NICE TA370 Bortezomib for previously untreated mantle cell lymphoma
 
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

 

For locally advanced squamous cell cancer of the head and neck in line with NICE TA145.

 

For previously untreated metastatic colorectal cancer in combination with panitumumab in line with NICE TA439 . 

 

For recurrent or metastatic squamous cell cancer of the head and neck in line with NICE TA473 

 

 
Link  Link to CDF secure application site
Link  NICE TA145 Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Link  NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
 
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Temozolomide (Temodal®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For the treatment of;


Recurrent malignant glioma (brain cancer) in line with NICE TA23


Newly diagnosed high-grade glioma in line with NICE TA121


This is via other specialist secondary care providers

 
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Link  NICE TA121: Glioma (newly diagnosed and high grade)
 
08.01.05  Expand sub section  Erlotinib to top
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Formulary
Red

For oncology indications

 
 
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds to top
Carboplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red

In combination with capecitabine in the adjuvant treatment of stage III (Dukes' C) colon cancer in Line With NICE TA100 

 
Link  NICE TA100:Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
 
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 
08.01.05  Expand sub section  Protein kinase inhibitors
Cytotoxic Drug Afatinib (Giotrif ®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For use in line with NICE TA310: 



Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:
the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
the person has not previously had an EGFR-TK inhibitor and
the manufacturer provides afatinib with the discount agreed in the patient access scheme.


Commissioned by NHSE

 
Link  NICE TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
 
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In line with NICE TA425 and NICE TA426

NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.


NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes

Commissioned by NHSE

 
Link  Link to CDF secure application site
Link  NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
 
Erlotinib (Tarceva®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer in line with NICE TA258 


Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) in line with NICE TA374 



Commissioned by NHSE

 
Link  NICE TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
 
Cytotoxic Drug Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Treating advanced breast cancer in combination with exemestane after endocrine therapy in line with NICE TA421

Commissioned by NHSE


 
Link  NICE TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
 
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red


In line With NICE TA192 and NICE TA374


Commissioned by NHSE

 
Link  NICE TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
 
Cytotoxic Drug Imatinib (Gilvec®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA86 & NICE TA326:

Adjuvant treatment of gastro-intestinal stromal tumours (GIST), in patients considered at high risk of relapse (based on risk criteria or mutation analysis), for up to 3 years. 

NICE TA209 specifies doses above 400mg not recommended.

NICE TA70 & TA426:
Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.

Commissioned by NHSE

 
Link  NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Link  NICE TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA70 Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  Link to CDF secure application site
 
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA425 and TA426.

NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes
(NHSE is the responsible commissioner)

NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.

Commissioned by NHSE

 
Link  NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
 
Palbociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA495 


With fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer in line with NICE TA619 

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
 
Regorafenib (Stivarga®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For previously treated unresectable or metastatic gastrointestinal stromal tumours in line with NICE TA488 


For previously treated advanced hepatocellular carcinoma in line with NICE TA555 

 
Link  Link to CDF secure application site
Link   NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
 
Ribociclib (Kisqali®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA496.


Commissioned by NHSE

 
Link   NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
 
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Commissioned by NHSE

 
Link  Link to CDF secure application site
 
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Advanced and/or metastatic renal cell carcinoma in line with NICE TA169 

Gastrointestinal stromal tumours in line with NICE TA179 .

Commissioned by NHSE 

 
Link  Link to CDF secure application site
Link   NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA169: Renal cell carcinoma - sunitinib
 
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
 
Link  Link to CDF secure application site
 
Tivozanib (Fotivda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For treating advanced renal cell carcinoma, in line with NICE TA512. 


 

 
Link  Link to CDF secure application site
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
 
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Docetaxel (Taxotere®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line With NICE TA101 & NICE TA109 

 
Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Link  NICE TA109: Breast cancer (early) - docetaxel
 
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red

In Line With NICE TA55  and TA389 


NICE TA389- The appraisal committee was unable to make recommendations on the use of these technologies for treating platinum-sensitive ovarian cancer beyond the first recurrence.

 
Link  NICE TA55:Guidance on the use of paclitaxel in the treatment of ovarian cancer
Link  NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
 
08.01.05  Expand sub section  Topoisimerase I inhibitors to top
Cytotoxic Drug Topotecan (Hycamtin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

 


For relapsed small-cell lung cancer in line with NICE TA184 


For recurrent and stage IVB cervical cancers in line with NICE TA183 

 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
 
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red


For the treatment of advanced soft tissue sarcoma in line with NICE TA185 

 
Link  NICE TA185 Trabectedin for the treatment of advanced soft tissue sarcoma
 
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For advanced breast cancer in line with NICE TA34

 

For early-stage HER2-positive breast cancer in line with NICE TA107

 

HER2-positive metastatic gastric cancer in line with NICE TA208 

 
Link  Link to CDF secure application site
Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
 
08.01.05  Expand sub section  Tretinoin
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Secondary care only, not to be prescribed in primary care.   

Amber 2

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber with Shared Care

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber

Considered suitable for primary care prescribing following specialist initiation/recommendation.  

Green

Considered appropriate for prescribing in both secondary and primary care. Suitable for initiation in primary care.   

netFormulary